Most kidney stones (KS) are composed of calcium oxalate and small increases in urine oxalate enhance the stone risk. Obesity is a risk factor for KS, and urinary oxalate excretion increases with increased body size. We previously established the obese ob/ob (ob) mice as a model (3.3-fold higher urine oxalate) to define the pathogenesis of obesity-associated hyperoxaluria (OAH). The purpose of this study was to test the hypothesis that the obesity-associated enhanced small intestinal paracellular permeability contributes to OAH by increasing passive paracellular intestinal oxalate absorption. ob Mice have significantly higher jejunal (1.6-fold) and ileal (1.4-fold) paracellular oxalate absorption ex vivo and significantly higher (5-fold) urine [ 13 C]oxalate following oral gavage with [ 13 C]oxalate, indicating increased intestinal oxalate absorption in vivo. The observation of higher oxalate absorption in vivo compared with ex vivo suggests the possibility of increased paracellular permeability along the entire gut. Indeed, ob mice have significantly higher fractions of the administered sucrose (1.7-fold), lactulose (4.4-fold), and sucralose (3.1-fold) excreted in the urine, reflecting increased gastric, small intestinal, and colonic paracellular permeability, respectively. The ob mice have significantly reduced gastrointestinal occludin, zonula occludens-1, and claudins-1 and -3 mRNA and total protein expression. Proinflammatory cytokines and oxidative stress, which are elevated in obesity, significantly enhanced paracellular intestinal oxalate absorption in vitro and ex vivo. We conclude that obese mice have significantly higher intestinal oxalate absorption and enhanced gastrointestinal paracellular permeability in vivo, which would likely contribute to the pathogenesis of OAH, since there is a transepithelial oxalate concentration gradient to drive paracellular intestinal oxalate absorption.
INTRODUCTION
Nephrolithiasis is one of the most common urologic diseases in western societies. It is a major source of patient discomfort and disability, lost working days, and care costs, with an annual economic cost of~$10 billion. Seventy to eighty percent of kidney stones are composed of calcium oxalate, and hyperoxaluria is a critical risk factor for kidney stones (13) . The risk for stone formation is affected by small changes in urine oxalate, and urinary oxalate is an important determinant of the level of supersaturation (15) . Importantly, a history of a single kidney stone is associated with a significantly increased risk of poor renal outcome, including chronic kidney disease and end-stage renal disease (1) .
Obesity, which is an important etiologic factor in the development of metabolic syndrome (23) , is a major avoidable cause of morbidity and mortality worldwide. Obesity and metabolic syndrome are risk factors for kidney stones (23, 49, 67) , and although a greater proportion of kidney stones in obese patients are uric acid stones, calcium oxalate kidney stones are also common in these patients (42) . Obese stone formers often have mild to moderate hyperoxaluria, and urinary oxalate excretion was reported to increase with increased body size in several population-based studies (35, 39, 56) . In addition, calcium oxalate kidney stones formers with metabolic syndrome have significantly higher urine oxalate compared with those without metabolic syndrome, and that urine oxalate significantly rises with increasing metabolic syndrome features (50) . Significantly higher urine oxalate is also seen in overweight children compared with normal weight children (51) . Given the increasing prevalence of obesity and metabolic syndrome, it is anticipated that the incidence of nephrolithiasis will continue to rise at a remarkable rate, not only in United States but also worldwide. This will certainly lead to a tremendous increase in the associated care costs and therefore dictate the need for defining the pathogenesis of obesity-associated hyperoxaluria.
The mammalian intestine plays an essential role in oxalate homeostasis by regulating the amount of absorbed dietary oxalate and providing an avenue for enteric oxalate excretion (26) . Small and large intestinal oxalate absorption is predominantly passive through the paracellular pathway (36) . Active transcellular intestinal oxalate secretion mediated by the anion exchanger SLC26A6 plays a critical role in preventing hyperoxaluria and related calcium oxalate kidney stones (20, 32) . It has been proposed that net intestinal absorption of dietary oxalate depends on the relative balance of absorption and SLC26A6-mediated secretion (36) . An increase in passive paracellular intestinal oxalate absorption and/or a reduction in active transcellular intestinal oxalate secretion could lead to hyperoxaluria and calcium oxalate kidney stones.
We previously established the obese ob/ob (ob) mice as a useful model to elucidate the molecular mechanisms underlying the obesity-associated hyperoxaluria (2) . The ob mice have significant hyperoxaluria (3.3-fold) compared with their lean controls, which is not due to overfeeding as shown by pairfeeding studies (2) . We find reduced active transcellular intestinal oxalate secretion, which is likely secondary to local intestinal and systemic inflammation, contributes to the pathogenesis of obesity-associated hyperoxaluria (2) . Higher small intestinal paracellular permeability was reported in the ob mice and in mice with high-fat diet-induced obesity (7, 9, 10) . Since small and large intestinal oxalate absorption is predominantly passive through the paracellular pathway (36) , the purpose of the present study was to test the hypothesis that the ob mice have increased passive paracellular intestinal oxalate absorption, which also contributes to the pathogenesis of obesityassociated hyperoxaluria. The ob mice have significantly enhanced passive paracellular jejunal and ileal oxalate absorption ex vivo. The ob mice also have significantly higher (5-fold) urinary excretion of [ 13 C]oxalate compared with controls, reflecting increased intestinal oxalate absorption in vivo. Assessment of gastrointestinal permeability in vivo using fractional urinary recovery of different sugar probes shows that the ob mice have significantly increased paracellular permeability along the entire gut. With the use of qPCR and immunoblotting, significantly reduced mRNA and total protein expression of the tight junction proteins occludin, zonula occludens-1 (ZO-1), claudin-1, and claudin-3 were observed in the stomach, jejunum, ileum, cecum, and/or distal colon of ob mice. Obesity is associated with increased systemic and intestinal inflammation (e.g., higher proinflammatory cytokines) and oxidative stress, which are known to disrupt intestinal barrier function and increase passive paracellular flux (6, 48) . We hypothesized that proinflammatory cytokines and/or oxidative stress might mechanistically contribute to the observed increased gastrointestinal paracellular permeability in ob mice and that they will directly enhance passive paracellular gastrointestinal oxalate absorption. Indeed, proinflammotory cytokines and the reactive oxygen species H 2 O 2 significantly enhanced passive paracellular intestinal oxalate absorption in vitro in human intestinal Caco2-BBE (Caco2) cells and ex vivo in mouse jejunal tissues.
MATERIALS AND METHODS
Animals. The ob mice and their lean littermate controls (males; 8 -12 wk old; on a C57BL/6J background) were obtained from the Jackson laboratory. BALB/c (males; 8 -12 wk old) were obtained from the Harlan laboratory. Mice were maintained in a specific pathogen-free facility, with free access to water and standard mouse chow (Harlan Teklad standard chow, no. 2918, which is the irradiated version of 2018). We measured the oxalate content of this chow and found it to be 10 mol/g chow. The oxalate content of a similar chow (no. 2018) was previously reported to be 12 mol/g chow (32) . The primary ingredients in this chow are grains (e.g., corn, wheat, and soybeans), which naturally contain oxalate (44, 52) , and therefore, they are the likely source of oxalate. Of note is that oxalate is not added to this chow. All animal studies were approved by the University of Chicago Institutional Animal Care and Use Committee and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Ex vivo intestinal loop studies. We utilized the ex vivo intestinal loop technique to assess the intestinal paracellular permeability as previously reported (21) . Briefly, immediately following euthanasia, 2 cm jejunal or ileal segments were obtained from the ob mice and their controls, and each segment was gently rinsed with PBS. One end of each segment was ligated with a silk suture, and the loop was filled with DMEM medium containing 1 mM mannitol, 0.1% FBS, 2 M [ 14 C]oxalate, and 0.02 M [ 3 H]mannitol, followed by closure of the other end. The loops were then transferred to wells with 2 ml of DMEM medium containing 1 mM mannitol, 0.1% FBS, 2 M oxalate, and 0.02 M mannitol and incubated at 37°C. Samples were taken at 30 min to determine the flux of [ 14 C]oxalate and [ 3 H]mannitol from the lumen to the medium outside bathing the loops. To assess whether H 2O2 also enhances passive paracellular oxalate and mannitol absorption in native intestinal epithelium as observed in C2 cells, jejunal loops from BALB/c mice were similarly developed and then treated with H2O2 (1 mM inside and outside the loop) or vehicle (control). Samples were taken at 60 and 90 min to determine the 30-min flux of [ 14 C]oxalate and [ 3 H]mannitol from the lumen to the medium outside bathing the loops.
Urine collection and oxalate measurements. Urine samples were collected by placing the mice individually in metabolic cages, in which they have free access to food and water, in vessels containing mineral oil to prevent evaporation. The urine samples were diluted 1:5 in 10 mM HCl and stored either at 4°C for the samples used for [ 13 C]oxalate measurements or at Ϫ80°C for the samples used for total oxalate measurements. Total urine oxalate was measured enzymatically using oxalate oxidase (Trinity Biotech Bray Ireland), employing sodium nitrite to prevent interference by ascorbic acid (34) . Urine [ 13 C]oxalate was measured by ion chromatography coupled with electrospray mass spectrometry (Metabolic Solutions, Nashua, NH). Urine creatinine was measured by a modified Jaffe alkaline picrate method (27) .
Assessment of gastrointestinal oxalate absorption in vivo. To assess whether the ob mice also have enhanced intestinal oxalate absorption in vivo as observed ex vivo, the ob mice and their controls were given a single dose of [ 13 C]oxalate (5 g/g) by oral gavage, followed by urine collection over the next 6-h period. The urine samples were diluted 1:5 in 10 mM HCl and stored at 4°C. Urine [ 13 C]oxalate was measured as described above.
Assessment of gastrointestinal paracellular permeability in vivo. Gastrointestinal paracellular permeability was assessed in vivo using disaccharide sugar probes as summarized below. Increased fractional urinary recovery of class 1 sugar probes (e.g., sucrose), class 2 probes (lactulose and mannitol), and class 3 (e.g., sucralose) has been shown to reflect increased paracellular permeability in the proximal gut, small intestine, and large intestine, respectively (45) . The ob mice and their controls (10 per group) had no access to food for~15 h (from 5 PM to 8 AM, during which they have free access to water) and were then given a solution containing the sugar probes sucrose (100 mg), mannitol (0.32 mg/g), lactulose (0.5 mg/g), and sucralose (6 mg) by oral gavage and the mice were then placed in metabolic cages and urine was collected over the next 24 h, during which they have access to food and water. Thymol, 100 l of a 10% solution in isopropanol, was added to each tube to prevent bacterial degradation of urinary sugars. The sugar probes were measured by HPLC in collaboration with Dr. Jon Meddings (University of Calgary, Calgary, Canada). In addition to sucralose (which is not metabolized by colonic bacteria) fractional urinary recovery described above, we also assessed colonic paracellular permeability by measuring creatinine fractional urinary recovery following gavage with creatinine as previously reported (55) . The ob mice and their controls (10 per group) had no access to food for~15 h (during which they have free access to water) as described above and were then given creatinine (0.6 mg/g) by oral gavage and the mice were then placed in metabolic cages for urine collection over 24 h. Urine creatinine was measured as described above.
Measurement of fluxes across jejunal tissues. To evaluate whether proinflammatory cytokines can increase passive paracellular intestinal oxalate absorption, BALB/c mice were treated with TNF (5 g ip; for 90 min) or vehicle (control), and then jejunal segments were isolated. The jejunal tissues were opened longitudinally along the mesenteric border, thoroughly cleansed by flushing with ice-cold saline, and then mounted as intact sheets in modified Ussing chambers (exposed tissue surface area of 0.30 cm 2 ; Physiological Instruments, San Diego, CA) as we previously reported (2, 5, 25 H]mannitol to the mucosal side, and then samples were collected from the serosal side every 30 min for 180 min and the measurements were averaged. Unlabeled oxalate (2 M) and mannitol (0.08 M) were added to the serosal bath. The radioactivity was measured by scintillation spectrometry. The validity of counting dual-labeled samples was verified using external standards, permitting the individual activities of [ 14 C]oxalate and [ 3 H]mannitol to be calculated on the basis of their relative counting efficiencies after minimizing and accounting for overlap in their energy spectra as previously reported (68) . The results are presented as the apparent permeability coefficients (P app) for oxalate and mannitol calculated as previously reported (36) , based on the following equation. J ϭ P app ϫ A ϫ [S], where J is the flux (mucosa-to-serosa), A is the exposed tissue surface area of the Ussing chamber, and [S] is the substrate concentration of [ 14 C]oxalate or [ 3 H]mannitol.
Cell culture and radioactive flux studies. Human intestinal Caco2-BBE (Caco2) cells were grown and maintained (including monitoring of the transepithelial resistance) as we previously reported (3, 24) . The oxalate flux studies described below were performed using confluent cells grown for 15-23 days postplating on 0.4-m collagen-coated polystyrene snapwell membrane filters (Corning, Corning, NY) in 12-mm inserts.
To evaluate whether proinflammatory cytokines can directly affect passive paracellular oxalate absorption, Caco2 cells grown on snapwell inserts were pretreated basolaterally with IFN-␥ (10 ng/ml) for 24 h, followed by addition of TNF-␣ (10 ng/ml) for another 24 h (with continued presence of IFN) or vehicle (control), and then the cells were mounted in Ussing chambers. To assess the effects of H 2O2 on passive paracellular oxalate absorption, Caco2 cells grown on snapwells were mounted in Ussing chambers and were then treated basolaterally with H2O2 (10 mM; Ref. 48) (21) . The results are reported as the average flux over 180 min and are presented as the apparent permeability coefficients (Papp) as described above.
SDS/PAGE and Western blotting. To obtain high-quality protein and RNA samples, epithelial cells were purified from the stomach, jejunum, ileum, cecum, and distal colon as previously reported (12) . SDS/PAGE and Western blotting was performed as we previously reported (3) . Briefly, equal amounts of protein lysates were separated by SDS/PAGE using 7.5% polyacrylamide gels, with subsequent electro-transfer to polyvinylidene difluoride (cat. no. IPVH00010; Immobilon-P, Millipore, Kankakee, IL). All immunoblots were stained with Ponceau S Solution [0.1% Ponceau S (wt/vol) in 5% acetic acid (vol/vol)] following transfer. Immunoblots were incubated overnight at 4°C with primary antibodies against occludin (cat. no. 33-1500; Invitrogen, Camarillo, CA; 1:500 dilution), ZO-1 (cat. no. 40-2200; Invitrogen; 1:1,000 dilution), claudin-1 (cat. no. 51-9000; Invitrogen; 1:1,000 dilution), claudin-3 (cat. no. C0144; AssayBio-Tech, Fremont, CA; 1:1,000 dilution), GAPDH (cat. no. sc-32233; Santa Cruz Biotechnology, Dallas, TX; 1:10,000 dilution), and ␤-actin (cat. no. A1978; Sigma-Aldrich, St. Louis, MO; 1:250,000 dilution). The strips then were washed in blotto and incubated for 1 h with horseradish peroxidase-conjugated secondary antibodies. Antibody reactivity was detected with the enhanced chemiluminescence system (SuperSignal West, cat. no. 34076; Thermo Fisher Scientific, Rockford, IL) according to the manufacturer's protocol.
Real-time PCR. RNA was extracted from the ob and control mice using the E.Z.N.A Total RNA Kit (cat. no. R6834-02; Omega Bio-tek, Norcross, GA). RNA was reverse transcribed and amplified with Power SYBR Green PCR Master Mix Kit (cat. no. A25777; Applied Biosystems, Foster City, CA). The real-time PCR (Bio-Rad iCycler Real-Time PCR Systems, Des Plaines, IL) conditions were as follows: initial denaturation at 95°C for 10 min; subsequently, 40 cycles of denaturation, annealing, and elongation (at 95°C for 15 s, 55°C for 20 s, and 72°C for 30 s, respectively). Mouse occludin was amplified with gene-specific primers (forward primer, 5=-GCGGAAGAGGTT-GACAGTCC-3=; reverse primer, 5=-ACTCCCCACCTGTCGTG-TAG-3=). Mouse ZO-1 was amplified with gene-specific primers (forward primer, 5=-AGGACACCAAAGCATGTGAG-3=; reverse primer, 5=-GGCATTCCTGCTGGTTACA-3 =). Mouse claudin-1 was amplified with gene-specific primers (forward primer, 5=-TCTAC-GAGGGACTGTGGATG-3=; reverse primer, 5=-TCAGATTCAGCA AGGAGTCG-3=). Mouse claudin-3 was amplified with gene-specific primers (forward primer, 5=-AAGCCGAATGGACAAAGAA-3=; reverse primer, 5=-CTGGCAAGTAGCTGCAGTG-3=). Mouse GAPDH was amplified as an internal control using gene-specific primers (forward primer, 5=-TCACCACAGTCCATGCCATC-3=; reverse primer, 5=-GACGGACACATTGGGGGTAG-3=). Relative occludin, ZO-1, and claudins-1 and -3 mRNA levels are expressed as a percentage of control normalized to GAPDH.
Materials when n Ͻ 10. The one-sample Wilcoxon signed-rank test was used for analyses looking at fold changes in mRNA expression levels. P Ͻ 0.05 was considered statistically significant.
RESULTS

Measurement of oxalate and mannitol absorptive fluxes in jejunal and ileal loops.
We previously established the ob mice [they have significantly higher (3.3-fold) urine oxalate compared with lean controls] as a useful model to define the pathogenesis of obesity-associated hyperoxaluria (2) . Higher small intestinal paracellular permeability was reported in the ob mice (7, 10) . Increased intestinal paracellular permeability was also reported in high-fat diet-induced obesity in mice (9) . Intestinal oxalate absorption is predominantly passive through the paracellular pathway (36) . We hypothesized that the obesity-associated enhanced intestinal paracellular permeability contributes to the obesity-associated hyperoxaluria by increasing passive paracellular intestinal oxalate absorption. To test this hypothesis, we utilized the mouse ex vivo intestinal loop model to assess the intestinal paracellular permeability (21) . We observed significantly higher jejunal [ 14 C]oxalate (1.6fold) and [ 3 H]mannitol (1.6-fold) fluxes from lumen to medium outside bathing the loops in the ob mice compared with controls ( Fig. 1A ; P Ͻ 0.04 for ob compared with control, with regards to oxalate and mannitol, by unpaired t-test). We also observed significantly higher ileal [ 14 C]oxalate (1.4-fold) and [ 3 H]mannitol (1.6-fold) absorptive fluxes ( Fig. 1B ; P Ͻ 0.02 and Ͻ 0.04 for ob compared with control, with regards to oxalate and mannitol, respectively, by unpaired t-test). Mannitol is a paracellular permeability marker (36), and [ 3 H]mannitol flux has been utilized as a measure of intestinal barrier function (21) . Since oxalate and mannitol fluxes were elevated to a similar extent in the ob mice compared with controls, it is possible that oxalate flux occurs through the same paracellular pathway as mannitol. These results confirm that the ob mice have a leaky intestinal epithelium as previously reported (7, 10) and suggest that the observed enhanced paracellular intestinal oxalate absorption contributes to the pathogenesis of obesity-associated hyperoxaluria.
Measurement of gastrointestinal oxalate absorption in vivo. To evaluate whether similar enhancement of oxalate absorption is also active in vivo as observed ex vivo, the ob mice and their controls were given a single dose of [ 13 C]oxalate (5 g/g) by oral gavage, followed by urine collection over the next 6-h period for urine [ 13 C]oxalate and total oxalate measurements.
Interestingly and as seen in Fig. 2 , the ob mice have a significantly higher (5-fold) fraction of the administered [ 13 C]oxalate excreted in the urine compared with controls (P Ͻ 0.02 for ob compared with controls, by unpaired t-test). These results indicate that the ob mice have remarkably enhanced intestinal oxalate absorption in vivo, which is most likely contributing to the observed hyperoxaluria and hence to the pathogenesis of obesity-associated hyperoxaluria.
Assessment of gastrointestinal paracellular permeability in vivo. The observation of a greater oxalate absorption in vivo compared with ex vivo in the jejunum and ileum suggests the possibility of increased paracellular permeability along the entire gut in our ob mice. To test this possibility, we assessed gastrointestinal paracellular permeability in vivo using fractional urinary recovery of disaccharide sugar probes. Class 1 sugar probes (e.g., sucrose) are rapidly degraded after leaving the stomach and entering the small intestine, and therefore, increased fractional urinary recovery of these probes following oral gavage reflects increased paracellular permeability in the proximal gut (45) . To evaluate whether the ob mice have increased gastric paracellular permeability, the ob mice and their controls were given sucrose (100 mg per mouse) by oral gavage, followed by 24 h urine collection. Shown in Fig. 3A , the ob mice have a significantly higher (1.7-fold; P Ͻ 0.02 by unpaired t-test) fraction of the administered sucrose excreted in the urine, reflecting enhanced proximal gut (including the stomach) paracellular permeability in vivo.
Class 2 sugar probes (e.g., lactulose and mannitol) are degraded by colonic bacteria after leaving the small intestine, 
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OBESITY AND URINE OXALATE EXCRETION and therefore, increased fractional urinary recovery of these probes following oral gavage has been used to reflect increased small intestinal paracellular permeability (45) . To determine whether the ob mice have enhanced small intestinal paracellular permeability, the ob mice and their controls were given lactulose (0.5 mg/g) and mannitol (0.32 mg/g) by oral gavage, followed by 24-h urine collection. The ob mice have significantly higher fractions of the administered lactulose (4.4-fold; Fig. 3B ; P Ͻ 0.002 by Mann-Whitney test), mannitol (3-fold; Fig. 3C ; P Ͻ 0.003 by Mann-Whitney test), and lactulose: mannitol ratio (1.52-fold; Fig. 3D ; P Ͻ 0.0001 by Mann-Whitney test), reflecting enhanced small intestinal paracellular permeability in vivo.
Class 3 sugar probes (e.g., sucralose) are not degraded by colonic bacteria, and therefore, increased fractional urinary recovery of these probes following oral gavage reflects increased colonic paracellular permeability. Sucralose crosses the intestinal membrane paracellularly and is not metabolized by colonic bacteria (57) , and therefore, it has been used as a marker for colonic paracellular permeability in animals and humans (45, 55, 57, 60) . To assess whether the ob mice have enhanced colonic paracellular permeability, the ob mice and their controls were given sucralose (6 mg per mouse) by oral gavage, followed by 24-h urine collection. As shown in Fig.  3E , the ob mice have a significantly higher (3.1-fold; P Ͻ 0.03 by unpaired t-test) fraction of the administed sucralose excreted in the urine, reflecting enhanced colonic paracellular permeability in vivo.
Creatinine is absorbed in the intestine through the paracellular pathway and, once absorbed, it is freely filtered at the glomerulus and excreted into the urine (60) . Therefore, urinary creatinine recovery is an indirect measure of intestinal paracellular creatinine absorption, and increased fractional urinary recovery of creatinine has been used as a marker for enhanced colonic paracellular permeability (55) . To provide further evidence for increased colonic paracellular permeability in the ob mice, the ob mice and their controls were given creatinine (0.6 mg/g) by oral gavage, followed by 24-h urine collection. As seen in Fig. 3F , the ob mice have a significantly higher (3.1-fold; P Ͻ 0.0006 by unpaired t-test) fraction of the administered creatinine excreted in the urine, confirming enhanced colonic paracellular permeability in these mice in vivo.
Evaluation of tight junction proteins in gastrointestinal tissues. Gastrointestinal paracellular permeability is controlled by several specific tight junction proteins, among which, occludin and ZO-1 have been proposed as key markers of tight junction integrity (4). To evaluate whether altered expression of occludin contributes to the observed enhanced paracellular permeability along the entire gut, gastric, jejunal, ileal, cecal, and distal colonic occludin mRNA expression levels were assessed by real-time PCR. As shown in Fig. 4 , significantly reduced occludin mRNA expression is observed in the stomach (~56%), jejunum (~80%), ileum (~73%), cecum (~41%), and distal colon (~43%) in the ob mice compared with controls (P Ͻ 0.05, 0.03, 0.05, 0.05, and 0.05, for ob compared with controls with regards to stomach, jejunum, ileum, cecum, and Following food removal for 15 h, the ob mice and their controls received sucrose (100 mg per mouse; n ϭ 10), lactulose (0.5 mg/g; n ϭ 9 -10), mannitol (0.32 mg/g; n ϭ 9 -10), sucralose (6 mg per mouse; n ϭ 10), or creatinine (0.6 mg/g; n ϭ 10) by oral gavage, and then the mice were placed in metabolic cages for 24 h for urine collection. The ob mice have significantly higher fractions of the administered sucrose, sucralose, and creatinine excreted in the urine (*P Ͻ 0.02, 0.03, and 0.0006, for ob compared with controls with regards to sucrose, sucralose, and creatinine, respectively, by unpaired ttest). The ob mice also have significantly higher fractions of the administered lactulose and mannitol excreted in the urine (*P Ͻ 0.002, 0.003, and 0.0001, for ob compared with controls with regards to lactulose, mannitol, and lactulose:mannitol ratio, respectively, by Mann-Whitney test).
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To evaluate whether the observed reduction in occludin mRNA expression is translated into decreased occludin protein expression, gastric, jejunal, ileal, cecal, and distal colonic occludin total protein expression levels were assessed by immunoblotting. Indeed, the ob mice have significantly reduced gastric (~48%), jejunal (~76%), ileal (~66%), cecal (~48%), and distal colonic (~50%) occludin total protein expression compared with controls (P Ͻ 0.02, 0.03, 0.03, 0.008, and 0.008 for ob compared with controls with regards to stomach, jejunum, ileum, cecum, and distal colon, respectively, by Mann-Whitney test) ( Fig. 5 , A-E, respectively; the densitometry of immunoblot results is shown in Fig. 5F ). Collectively, these findings show that the ob mice have significantly reduced gastric, jejunal, ileal, cecal, and distal colonic occludin mRNA ( Fig. 4 ) and total protein ( Fig. 5 ) expression levels, which are likely contributing to the observed in vivo enhanced gastric, small intestinal, and colonic paracellular permeability and hence to the pathogenesis of obesity-associated hyperoxaluria.
We similarly assessed gastric, jejunal, ileal, cecal, and distal colonic ZO-1 mRNA expression levels to evaluate whether there is altered mRNA expression of ZO-1 in the ob mice. As seen in Fig. 6A , the ob mice have significantly reduced gastric (~46%), jejunal (~44%), ileal (~51%), cecal (~53%), and distal colonic (~57%) ZO-1 mRNA expression levels compared with controls (P Ͻ 0.02, 0.02, 0.03, 0.05, and 0.05, for ob compared with controls with regards to stomach, jejunum, ileum, cecum, and distal colon, respectively, by one-sample Wilcoxon signedrank test). These results show that the ob mice have significantly reduced gastric, jejunal, ileal, cecal, and distal colonic ZO-1 mRNA expression levels. Using immunoblotting, we also showed that the ob mice have significantly reduced cecal (~51%; Fig. 6B ) and distal colonic (~69%; Fig. 6C ) ZO-1 total protein expression compared with controls (P Ͻ 0.03 and 0.03 for ob compared with controls with regards to cecum and distal colon, respectively, by Mann-Whitney test). Of note is that the same antibody that recognizes the expected ZO-1 band (~225 kDa) in the cecum and distal colon and it recognizes many bands with sizes ranging from Ͻ100 to Ͼ250 kDa in the jejunum and ileum. We tried a different anti-ZO-1 antibody but it recognizes a band~120 -130 kDa rather than the expected band~225 kDa in the jejunum and ileum. Taken together, these findings show that the ob mice have significantly reduced gastric, jejunal, ileal, cecal, and distal colonic ZO-1 mRNA ( Fig. 6A ) and cecal and distal colonic ZO-1 total protein (Fig.  6 , B and C) expression levels, which are likely contributing to the observed in vivo enhanced gastric, small intestinal, and Values are means Ϯ SE for 4 -5 independent experiments of relative occludin abundance to ␤-actin and are presented as a percentage of the control value. The ob mice have significantly reduced gastric, jejunal, ileal, cecal, and distal colonic occludin total protein expression levels (*P Ͻ 0.02, 0.03, 0.03, 0.008, and 0.008 for ob compared with controls with regards to stomach, jejunum, ileum, cecum, and distal colon, respectively, by Mann-Whitney test).
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In addition to occludin and ZO-1, claudins also play a crucial role in the regulation of the intestinal paracellular permeability (46) . Claudins-1 and -3 are associated with a much tighter barrier function [i.e., lower paracellular permeability] (46). To determine whether altered expression of claudin-1 also contributes to the observed enhanced gastrointestinal paracellular permeability, gastrointestinal claudin-1-mRNA expression levels were similarly assessed. We observed a significant reduction in jejunal (~56%) and ileal (~36%) claudin-1 mRNA expression levels in the ob mice compared with controls ( Fig. 7A ; P Ͻ 0.05 and 0.03 for ob compared with controls with regards to jejunum and ileum, respectively, by one-sample Wilcoxon signed-rank test). We also observed significant reduction in jejunal (~50%; Fig. 7, B and D) and ileal (~27%; Fig. 7 , C and D) claudin-1 total protein expression levels in the ob mice compared with controls (P Ͻ 0.04 and 0.03 for ob compared with controls with regards to jejunum and ileum, respectively, by Mann-Whitney test). There are no significant differences in gastric, cecal, and distal colonic claudin-1 mRNA and total protein expression levels (data not shown). These results indicate that reduced jejunal and ileal claudin-1 mRNA and total protein expression also likely contributes to the enhanced small intestinal paracellular permea-bility seen in vivo in the ob mice and hence to the pathogenesis of obesity-associated hyperoxaluria.
We similarly evaluated whether altered expression of claudin-3 contributes to the enhanced gastrointestinal paracellular permeability observed in the ob mice. Significant reductions in jejunal (~43%) and ileal (~50%) claudin-3 mRNA expression levels were observed in the ob mice compared with controls ( Fig. 8A ; P Ͻ 0.02 and 0.03 for ob compared with controls with regards to jejunum and ileum, respectively, by one-sample Wilcoxon signed-rank test). We also observed a significant reduction in jejunal (~49%; Fig. 8, B and D) and ileal (~54%; Fig. 8, C and D) claudin-3 total protein expression levels in the ob mice compared with controls (P Ͻ 0.05 and 0.03 for ob compared with controls with regards to jejunum and ileum, respectively, by Mann-Whitney test). There are no significant differences in gastric, cecal, and distal colonic claudin-3 mRNA and total protein expression levels (data not shown). Collectively, these data indicate that decreased jejunal and ileal claudin-3 mRNA and total protein expression also likely contributes to the enhanced small intestinal paracellular permeability observed in vivo in the ob mice and hence to the pathogenesis of obesity-associated hyperoxaluria.
Effects of proinflammatory cytokines on oxalate and mannitol absorptive fluxes. Obesity is characterized by chronic systemic inflammation (16) and the ob mice have significantly 
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OBESITY AND URINE OXALATE EXCRETION higher plasma levels of several proinflammatory cytokines [e.g., TNF-␣ (TNF), IFN-␥ (IFN), IL-1␤, and IL-6] compared with their lean controls (7) . Obesity is also characterized by increased small intestinal inflammation (18, 62) . Importantly, we previously confirmed that our ob mice have increased systemic and small intestinal wall inflammation under our housing conditions (2) . Since proinflammatory cytokines are known to disrupt intestinal barrier function and increase passive paracellular flux (6), we hypothesized that proinflammatory cytokines play an important role in the increased gastrointestinal paracellular permeability and enhanced passive paracellular intestinal oxalate absorption observed in the ob mice. To test this hypothesis, we evaluated whether proinflammatory cytokines can directly affect passive paracellular oxalate flux in Caco2 cells. To this end, Caco2 cells grown on snapwell inserts were pretreated basolaterally with IFN (10 ng/ml) for 24 h, followed by addition of TNF (10 ng/ml) for another 24 h (with continued presence of IFN) or vehicle (control), and then the cells were mounted in Ussing chambers. As seen in Fig. 9A , pretreatment with IFN and TNF (IFN ϩ TNF), which synergize to induce intestinal barrier dysfunction (65) , led to a threefold increase in the [ 3 H]mannitol and [ 14 C]oxalate absorptive fluxes and to a similar extent (P Ͻ 0.0008 and Ͻ 0.0006 for IFN ϩ TNF compared with control, with regards to oxalate and mannitol, respectively, by unpaired t-test), indicating that the observed oxalate absorptive flux is passive and paracellular. Under these conditions, the transepithelial resistance was significantly reduced (~42%) in the (IFN ϩ TNF)-treated monolayers but no change was seen in control monolayers, confirming previous findings (65) . These results show that IFN 
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OBESITY AND URINE OXALATE EXCRETION and TNF can directly increase passive paracellular oxalate absorption in vitro, and therefore, they might play an important role in the observed hyperoxaluria by potentially increasing passive paracellular intestinal oxalate absorption in vivo.
Although Caco2 cells closely resemble the native epithelium, confirmation of the in vitro findings in vivo is of paramount physiological and translational interest. To this end, BALB/c mice were given TNF (5 g ip 1 time) or vehicle, and then jejunal segments were isolated and mounted in Ussing chambers 90 min later. Interestingly, TNF caused a significant increase (1.9-fold) in [ 3 H]mannitol and [ 14 C]oxalate absorptive fluxes ( Fig. 9B ; P Ͻ 0.008 and P Ͻ 0.003 for TNF-␣ compared with control, with regards to oxalate and mannitol, respectively, by unpaired t-test). These findings confirm that similar regulation is also active in vivo as observed in vitro and provide further evidence that proinflammatory cytokines likely play an important role in the observed hyperoxaluria by increasing passive paracellular intestinal oxalate absorption.
Effects of oxidative stress on oxalate and mannitol absorptive fluxes. Obesity is also associated with increased oxidative stress [elevated plasma levels of reactive oxygen species] in humans and mice (22) . Plasma levels of the reactive oxygen species H 2 O 2 are significantly elevated in the obese KKAy mice compared with controls (22) , and H 2 O 2 is known to disrupt intestinal barrier function and to increased passive paracellular permeability (48) . We hypothesized that the obe-sity-associated increase oxidative stress contributes to obesityassociated hyperoxaluria by increasing passive paracellular intestinal oxalate absorption. To test this hypothesis, we used H 2 O 2 to induce oxidative stress in Caco2 cells. Caco2 cells grown on snapwells were mounted in Ussing chambers and were then treated basolaterally with H 2 O 2 [10 mM (48) ] or vehicle (control). Shown in Fig. 10A, H Fig. 10B ; P Ͻ 0.009 and P Ͻ 0.05 for H 2 O 2 compared with control, with regards to oxalate and mannitol, respectively, by Mann-Whitney test), reflecting the physiological relevance of the in vitro findings. Collectively, these results show that H 2 O 2 significantly enhances passive paracellular intestinal oxalate absorption both in vitro and ex vivo and therefore support our hypothesis that the obesity-associated increased oxidative stress likely contributes to the obesity-associated hyperoxaluria by increasing passive paracellular intestinal oxalate absorption. 
DISCUSSION
In the present study we tested the hypothesis that the obesity-associated enhanced small intestinal paracellular permeability contributes to the obesity-associated hyperoxaluria by increasing passive paracellular intestinal oxalate absorption. The ob mice have significantly increased passive paracellular jejunal and ileal oxalate absorption ex vivo. Studies in which the ob mice and their controls were given [ 13 C]oxalate by oral gavage revealed that the ob mice have significantly higher (5-fold) fractional urinary excretion of [ 13 C]oxalate compared with controls, indicating increased intestinal oxalate absorption in vivo. The observation of higher oxalate absorption in vivo compared with ex vivo suggests the possibility of increased paracellular permeability along the entire gut. Utilizing fractional urinary recovery of different sugar probes and creatinine to assess gastrointestinal permeability, we have shown that the ob mice have significantly higher gastric, small intestinal, and colonic paracellular permeability in vivo. Using quantitative PCR and immunoblotting, we have shown that the observed gastrointestinal barrier dysfuction and the enhanced in vivo paracellular permeability are associated with molecular alterations including reduced occludin, ZO-1, and claudins-1 and -3 mRNA and total protein expression. Proinflammatory cytokines and oxidative stress, which are elevated in obesity, significantly enhanced paracellular intestinal oxalate absorption in vitro and ex vivo, suggesting that proinflammatory cytokines and/or oxidative stress might play important pathogenic roles in the pathogenesis of obesity-associated hyperoxaluria. Worthy of mentioning is that in addition to enhanced intestinal oxalate absorption, the increased urinary excretion of [ 13 C]oxalate could also potentially be due to reduced active transcellular intestinal oxalate secretion in vivo in the ob mice. Of interest in this regard is that we previously found significantly reduced (31%) active transcellular jejunal oxalate secretion ex vivo in the ob mice (2) .
Gastrointestinal paracellular permeability is tightly regulated by several tight junction proteins, including occludin, ZO-1, and claudins (4). The paracellular barrier has two physiologic components. A high-capacity charge-selective porelike pathway for solutes Ͻ4 Å in radius, and this component is mostly regulated by claudins (4) . The second component is a charge-and size-independent low capacity leak pathway for solutes Ͼ4 Å in radius (4) . On the basis of its structure and negative charge size, oxalate has an effective radius of~3-4 Å (64). However, oxalate calculated size increases upon complexing with calcium, magnesium, and sodium (8) . Oxalate has been shown to traverse the tight junction through the lowcapacity leak pathway (36) . Similar to oxalate, mannitol (a paracellular permeability marker and has an estimated size of 4.2 Å; Ref. 4) was also shown to traverse the tight junction through the leak pathway (61) . ZO-1 knockdown, which selectively enhances the permeability of the low capacity leak pathway for larger molecules (61) , equivalently increased oxalate and mannitol absorptive fluxes across MDCK II cells (36) , indicating that oxalate and mannitol traverse the tight junction through the leak pathway. We now find that the ob mice have significantly higher equivalent jejunal and ileal [ 14 C]oxalate and [ 3 H]mannitol absorptive fluxes ex vivo, indicating that oxalate and mannitol are absorbed through the same paracellular pathway. Importantly, the ob mice have signifi-cantly higher (5-fold) urinary excretion of [ 13 C]oxalate compared with controls following oral gavage with [ 13 C]oxalate, indicating increased gastrointestinal oxalate absorption in vivo. We also showed that the ob mice have increased gastrointestinal paracellular permeability, which is associated with molecular alterations including reduced occludin, ZO-1, and claudins-1 and 3 mRNA and total protein expression. Although previous studies have shown higher small intestinal paracellular permeability due to altered occludin and ZO-1 protein expression in ob mice (7, 10) , to our knowledge this study is the first to show enhanced gastric and colonic paracellular permeability in ob mice in vivo. Worthy of mentioning is that Stenman et al. (53) did not show increased jejunal and colonic paracellular permeability, assessed ex vivo by measuring the translocation of 4-kDa fluorescein isothiocyanate dextran in tissues mounted in Ussing chambers, in ob mice. Differences in methodology, including the fact that the ob mice in this study (53) were obtained from Charles River in Italy while their wild-type controls were obtained from Charles River in Germany, might explain this discrepancy in results. Our ob mice and their lean littermate controls were obtained from the Jackson laboratory. Increased intestinal paracellular permeability and decreased expression of occludin and ZO-1 were also reported in high-fat diet-induced obesity in mice (9) . Collectively, our findings show that enhanced gastrointestinal passive paracellular oxalate absorption plays an important role in the hyperoxaluria observed in the ob mice and therefore in the pathogenesis of obesity-associated hyperoxaluria. It should be noted that passive paracellular gastric oxalate absorption has been reported (26) , and future studies will evaluate gastric paracellular oxalate absorption in ob mice and their controls.
The observed enhanced gastrointestinal paracellular permeability and increased paracellular intestinal oxalate absorption likely play an important role in the pathogenesis of obesityassociated hyperoxaluria. We hypothesized that proinflammatory cytokines are major players in the observed increased gastrointestinal paracellular permeability and enhanced intestinal oxalate absorption based on the following observations: Obesity is characterized by chronic systemic inflammation in humans and animals (16, 38, 59) , and the ob mice have significantly higher circulating levels of several proinflammatory cytokines as described above (7) . In addition to chronic systemic inflammation, an increase in small intestinal inflammation was also observed in the db/db (another obesity mouse model) mice and obese human subjects (18, 62) . Importantly, we demonstrated increased systemic and small intestinal wall inflammation (including higher TNF and IFN levels) in our ob mice (2) . Proinflammatory cytokines are known to disrupt intestinal barrier function (by altering the expression of several tight junction proteins) and increase passive paracellular flux (6) . The latter could lead to enhanced passive paracellular intestinal oxalate absorption since intestinal oxalate absorption is predominantly passive through the paracellular pathway (36) . Interestingly, we found that pretreatment with IFN and TNF caused a threefold increase in the [ 3 H]mannitol and [ 14 C]oxalate absorptive fluxes in Caco2 cells. The physiological relevance of the in vitro findings is underscored by the observation that TNF caused a 1.9-fold in [ 3 H]mannitol and [ 14 C]oxalate absorptive fluxes across jejunal tissues isolated from BALB/c mice and mounted ex vivo in Ussing chambers. Of interest in this regard is that we have previously shown that G10 OBESITY AND URINE OXALATE EXCRETION proinflammatory cytokines significantly decreased oxalate transport in Caco2 cells by reducing SLC26A6 mRNA and total protein expression, as well as significantly reducing active mouse jejunal oxalate secretion (2) , and therefore, they likely contribute to the pathogenesis of obesity-associated hyperoxaluria by reducing active transcellular intestinal oxalate secretion. Collectively, our findings support the hypothesis that proinflammatory cytokines likely play an important role in the pathogenesis of obesity-associated hyperoxaluria by enhancing both passive paracellular intestinal oxalate absorption and reducing active transcellular intestinal oxalate secretion. Therefore, it will be of significant therapeutic interest to evaluate in future studies whether neutralizing antibodies against TNF and IFN will normalize and/or ameliorate the hyperoxaluria observed in the ob mice.
In addition to proinflammatory cytokines, we hypothesized that oxidative stress also plays an important role in the pathogenesis of obesity-associated hyperoxaluria. Obesity is associated with increased oxidative stress in humans and mice (22) . Adipocytes produce significantly higher H 2 O 2 in the obese KKAy mice, and it is the major source of the elevated plasma levels of H 2 O 2 in these mice (22) . The increased oxidative stress in adipocytes leads to dysregulated production of adipocytokines, including increased expression of TNF and IL-6, and it plays an important role in the pathogenesis of the obesity-associated metabolic syndrome (22) . H 2 O 2 disrupts intestinal barrier function and increases passive paracellular permeability through mechanisms including reduced expression of occludin and ZO-1 (48, 66) . Our finding that H 2 O 2 enhances passive paracellular intestinal oxalate absorption both in vitro and ex vivo suggests that the obesity-associated increased oxidative stress can directly contribute to the pathogenesis of obesity-associated hyperoxaluria by increasing passive paracellular intestinal oxalate absorption. It can also indirectly contribute to increased paracellular intestinal oxalate absorption by increasing the expression of proinflammatory cytokines, which we have shown to increase passive paracellular intestinal oxalate absorption. In addition to the obesityassociated enhanced systemic oxidative stress, an increase in small intestinal oxidative stress is also observed in the obese db/db mice and obese human subjects (18, 62, 63) , which might also be contributing to the observed increased gastrointestinal paracellular permeability and enhanced intestinal oxalate absorption. Besides inflammation and oxidative stress we hypothesize that the obesity-associated altered gut microbiome (40, 41) also contributes to the pathogenesis of obesity-associated hyperoxaluria, and future studies will test this hypothesis.
ob mice are hyperphagic (43) , and therefore, it is crucial to make sure that the observed hyperoxaluria is not mainly coming from the diet as a result of overeating. To address this important issue, we pair-fed the ob mice and their controls and still found that the ob mice have significant hyperoxaluria (2) , indicating that the observed hyperoxaluria is not due to overeating as a result of the hyperphagia. Since the obesity phenotype in the ob mice is primarily due to leptin deficiency (43), we previously asked the question whether leptin deficiency contributes to the observed hyperoxaluria. We found that leptin regulates intestinal oxalate transport (unpublished data) in a manner that is expected to result in reduced urinary oxalate excretion (rather than the increased excretion observed in the ob mice) in the setting of leptin deficiency in the ob mice, indicating that leptin deficiency does not play a role in the observed hyperoxaluria. Of note is that the ob mice on the C57BL/6J background have mild to moderate transient hyperglycemia, developing around age 2-3 mo and subsiding by age 4 -5 mo (14, 28, 31) . We observed similar hyperoxaluria in ob mice ages 8 -20 wk and 21-53 wk, indicating that it is independent of the diabetic phenotype. The finding of similar hyperoxaluria in the presence (ages 8 -20 wk) and absence (age 21-53 wk) of hyperglycemia in the ob mice indicates that the observed hyperoxaluria is not driven by the hyperglycemia.
Nephrolithiasis continues to be a world-wide major public health problem. Unfortunately, hyperoxaluria remains without specific therapy, and the risk of stone formation rises in both sexes at urinary oxalate levels traditionally considered normal (25-30 mg/day) (15) . Better understanding of the molecular mechanisms leading to secondary hyperoxaluria, including obesity-associated hyperoxaluria, could lead to the development of novel therapies for hyperoxaluria. Our finding that enhanced passive paracellular gastrointestinal oxalate absorption, which is likely mediated by the obesity-associated increased systemic and intestinal inflammation and oxidative stress, significantly contributes to the pathogenesis of obesityassociated hyperoxaluria, has potential translational relevance. Importantly, these findings should open the door for specific therapeutic intervention for the obesity-associated hyperoxaluria, including evaluating the in vivo therapeutic potential of neutralizing antibodies against the involved proinflammatory cytokines, as well as other modulators that can reduce reactive oxygen species production by adipocytes and/or improve gastrointestinal barrier function. By reducing gastrointestinal passive paracellular oxalate absorption and subsequent urinary oxalate excretion, such therapeutic interventions will have the potential to normalize and/or ameliorate the obesity-associated hyperoxaluria.
Our study findings have potential pathophysiologic and translational relevance to human obesity as shown by the following observations. Increased small intestinal paracellular permeability was reported in obese females (58) . This was assessed as an increase in urinary excretion of lactulose following an oral dose and that lactulose excretion showed positive correlation with waist and abdominal circumference (58) . This would likely enhance passive paracellular intestinal oxalate absorption, potentially leading to hyperoxaluria, since there is a transepithelial oxalate concentration gradient (higher luminal oxalate compared with plasma) to drive paracellular oxalate absorption in real life. Claudins-1, -3 and -5 are associated with a much tighter barrier function [i.e., lower paracellular permeability] (46) . The study by Casselbrant et al. (11) provides another evidence for small intestinal barrier dysfunction (i.e., leaky epithelium) due to altered tight junction proteins in obese human subjects. Paired intraindividual jejunal mucosal samples were obtained from obese subjects at the time of bariatric surgery and 6 -8 mo later (11) . Compared with baseline, increased expression of claudins-3 and -4 was observed after surgery, but there was no change in claudin-2 expression (11) . In addition, a positive linear correlation between the epithelial electrical resistance and claudin-3 protein expression was seen, implying decreased jejunal paracellular permeability following weight loss (11) . Observing an increase in claudin-3 (i.e., reflecting reduced baseline claudin-3 expres-G11 OBESITY AND URINE OXALATE EXCRETION sion) expression is in agreement with our findings that jejunal claudin-3 mRNA and total protein expression levels are significantly reduced in the ob mice. In addition, our findings might also have pathophysiologic relevance for other conditions characterized by increased intestinal paracellular permeability and increased intestinal and/or systemic inflammation and oxidative stress, including inflammatory bowel disease, celiac disease, and diabetes mellitus (17, 19, 33, 47) . Our findings could potentially explain the association among inflammatory bowel disease, celiac disease, diabetes mellitus, and nephrolithiasis with regards to increased urinary oxalate excretion.
Approximately fifty percent of urine oxalate is derived from diet and fifty percent is derived from endogenous hepatic oxalate synthesis (30) . Diet is a crucial factor in oxalate homeostasis since it provides oxalate that will be absorbed by the gastrointestinal tract. It also provides different oxalate precursors (e.g., glycine, phenylalanine, tyrosine, tryptophan, and carbohydrates, all of which exist in the chow) for endogenous hepatic oxalate synthesis (29, 37) . We have previously shown that the hyperoxaluria observed in the ob mice is not due to overeating as shown by pair-feeding studies (2) . In addition, we also showed that dietary oxalate removal greatly ameliorated the observed hyperoxaluria, confirming that it is largely enteric in origin (2) .
Of note is that our studies were conducted in male ob and control mice. However, we observed in preliminary studies that female ob mice also have significant hyperoxaluria (~2.8-fold) compared with lean controls. We observed some difficulties when dealing with the female ob mice including finding bedding within their vaginal cavities mixed with smegma (a combination of shed skin cells, skin oils, and moisture) and in some cases blood, as well as an increased frequency of urine scalding (an acidic substance that can burn and irritate the skin). Cleaning this out is quite time consuming, and we concentrated on male ob mice. Given a 2.8-fold hyperoxaluria, an enhanced gastrointestinal paracellular permeability and increased passive gastrointestinal oxalate absorption will be expected in in the female ob mice as observed in male ob mice, and this will be confirmed in future studies. Since estrogen (17␤-estradiol) is well known to influence different aspects of the immune system function (54) , future studies will evaluate whether female ob mice have less intestinal inflammation compared with the males.
In summary, we have shown that obese mice have significantly increased intestinal oxalate absorption in vivo and remarkably enhanced passive paracellular permeability along the entire gut, which are associated with molecular alterations including reduced occludin, ZO-1, and claudins-1 and -3 mRNA and total protein expression. The observed increase in gastrointestinal paracellular permeability and enhanced passive intestinal oxalate absorption are likely mediated by the obesityassociated systemic/intestinal inflammation and oxidative stress. Since there is a transepithelial oxalate concentration gradient to drive passive paracellular oxalate absorption in real life, the observed enhanced gastrointestinal paracellular permeability and increased paracellular intestinal oxalate absorption are most likely contributing to the hyperoxaluria seen in the ob mice and therefore to the pathogenesis of obesityassociated hyperoxaluria.
